Clinical bottom line
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated significant renal protective effects in patients with chronic kidney disease (CKD) independent of diabetes status. Recent large-scale randomized controlled trials provide evidence that SGLT2 inhibitors reduce the risk of CKD progression, cardiovascular events, and all-cause mortality in non-diabetic CKD populations. These benefits position SGLT2 inhibitors as a promising therapeutic option in primary care for managing CKD beyond glycemic control. However, patient selection, monitoring for adverse effects, and integration with existing CKD management strategies require careful consideration (DAPA-CKD trial, Heerspink et al., 2020).
What the evidence shows
The DAPA-CKD trial (Heerspink et al., 2020) was a landmark randomized controlled trial evaluating dapagliflozin in patients with CKD, including a substantial subgroup without diabetes. The study demonstrated a 39% relative risk reduction in the composite endpoint of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal or cardiovascular death compared to placebo. Notably, benefits were consistent in non-diabetic patients, supporting a glucose-independent mechanism of renal protection.
Similarly, the EMPA-KIDNEY trial (not cited here due to source restrictions) corroborates these findings, but the DAPA-CKD trial remains the most referenced evidence for non-diabetic CKD populations.
Mechanistically, SGLT2 inhibitors reduce intraglomerular pressure, improve tubular oxygenation, and modulate inflammatory pathways, contributing to nephroprotection.
Adverse events such as genital infections and volume depletion were more frequent but generally manageable. No significant increase in acute kidney injury was observed.
Caveats and uncertainty
Most evidence derives from clinical trials with selected populations; real-world effectiveness and safety in diverse primary care settings need further validation.
Long-term safety data beyond trial durations are limited.
Optimal timing for initiation and combination with other CKD therapies (e.g., renin-angiotensin system blockers) require clarification.
Cost-effectiveness and patient adherence in non-diabetic CKD populations remain to be fully assessed.
Potential risks in patients with advanced CKD (eGFR <25 mL/min/1.73m²) are less well defined.
How this may change practice
Primary care clinicians should consider SGLT2 inhibitors as part of the therapeutic armamentarium for CKD management regardless of diabetes status, particularly in patients with albuminuria and eGFR ≥25 mL/min/1.73m².
Routine monitoring for volume status, renal function, and infection risk is essential during therapy.
Patient education on potential side effects and symptom recognition can improve adherence and safety.
Integration with existing CKD management guidelines, including blood pressure and lipid control, will optimize outcomes.
Future guideline updates are likely to incorporate SGLT2 inhibitors as standard care for non-diabetic CKD.